AR and prostate adenocarcinoma: Neuroendocrine prostate cancer (NEPC) is a sub-variant of aggressive prostate cancer that rarely arises de novo, but most frequently emerges after androgen receptor (AR)-targeted therapies for prostate adenocarcinoma (1).